Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Cell Division

Figure 2

From: Complement susceptibility in glutamine deprived breast cancer cells

Figure 2

Neutralization of CD59 enhanced complement-mediated lysis. In A through D, Bcap37 and MCF7 cells (1 × 105) were sensitized with 20 μg of rabbit antibody to β2-microglobulin (anti-β2M) with or without specified doses of mAb-YTH53.1 (anti-CD59). Background LDH activity was obtained with unsensitized cells similarly incubated with 25% NHS for 4.5 hours to provide a numerical value that was subtracted from experimental values. Experimental antibody combinations are represented as follows: 1) 10 μg anti-β2M alone (28.0% lysis ± 1.7). 2) 20 μg anti-β2M alone (42.3% lysis ± 2.9). 3) 20 μg mAb-YTH53.1 alone (11.3% lysis ± 1.5). 4) 20 μg anti-β2M + 5 μg mAb-YTH53.1 (43.3% lysis ± 2.1). 5) 20 μg anti-β2M + 10 μg mAb-YTH53.1 (53% lysis ± 4.8). 6) 20 μg anti-β2M + 20 μg mAb-YTH53.1 (59% lysis ± 4.9).

Back to article page